News

AddToAny

Google+ Facebook Twitter Twitter

Genetic risk for IBD patients

In a retrospective study, investigators found that a combination of rare and common genetic variants in some inflammatory bowel disease (IBD) patients significantly increased their risk of developing clot-causing thromboembolic diseases.

Senior author Dermot P McGovern said: “The genetic signature we identified more than doubled the risk of developing potentially fatal blood clots in approximately one in seven IBD patients.

“While the risk for blood clots in IBD patients could be attributed to episodes of severe inflammation in the gastrointestinal tract that led to surgery, or to a side-effect of some medications, very little was known about the impact of genetics on that risk.”

Researchers used whole-genome sequencing and genotyping to assess 792 IBD patients and then identify patterns associated with the development of venous or arterial thromboembolisms.  

bit.ly/2Il3Zrj

Image Credit: Shutterstock

Related Articles

CRISPR-Cas9 gene editing complex, illustration.Image credit - Science-Photo-Library-f0248864

Activating genes using CRISPR technology

There are over 7000 different rare genetic diseases, and often it can be a significant challenge and take a long time to receive a correct diagnosis.

Blue helix human DNA structure-Image credit-shutterstock-1669326868

The search for genes that cause diseases

A new statistical tool developed by researchers at the University of Chicago improves the ability to find genetic variants that cause disease.

pathogenspreadhr-CREDIT-spooky-pooka

Figuring out the threats: Problem-solving with genomics

As the COVID-19 enquiry continues to unpick the tangled threads of the pandemic response, little has been said about one of the most effective weapons against the SARS-Cov-2 virus – pathogen genomics.

breast cancer cells - CREDIT - Science Photo Library-c0559159

Breast cancer cells’ self-sacrifice is potential cause of relapse

For patients with early-stage breast cancer, there is a 7% to 11% chance of relapse within five years after receiving initial treatment.

Top